KKR-Backed Catalio Seeks $500 Million for AI-Healthcare Deals
THE SO WHAT
Catalio raising another $500M for AI healthcare in 16 months shows institutional capital believes AI-native clinical and infrastructure plays are ready for scale, not just pilots. Health operators should expect faster vendor turnover and more M&A—lock in data rights and integration terms so you’re not exposed when your AI supplier changes hands.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAnthropic Stands Alone as Rest of US IPO Market Slows to a Crawl
If Anthropic is one of the few IPOs investors can count on in a stalled pipeline, frontier AI is becoming a liquidity outlier. Late-stage startups should read this as a bar reset—unless you’re in a similar perceived “must-own” category, plan for extended private capital dependence or structured exits.
Startups & VentureAnthropic’s IPO Momentum as CoreWeave Rattles AI Trade
Anthropic’s IPO prep alongside CoreWeave talking about “unlimited” capital for data centers underscores how AI infra is becoming its own asset class, not just cloud capex. If you depend on GPU access, treat your infra providers like strategic partners—lock in terms, diversify, and monitor their financing risk as closely as you monitor model roadmaps.
Startups & VentureInside Blackstone’s Massive Bet on the AI Boom
Blackstone spreading capital across data centers, power, cooling, chip financing, and equity in AI companies shows private markets are building a full-stack exposure to AI, not just picking model winners. For operators, this means more non-cloud options for financing and hosting AI workloads—but also more sophisticated landlords on power and utilization covenants.
Startups & VentureSunbound, which makes software for handling billing, insurance claims, and payments for senior living operators, raised a $24M Series A led by TTV Capital
A $24M Series A into Sunbound’s billing and claims stack for senior living shows capital is chasing vertical fintech where demographics guarantee volume and complexity. If you sell into healthcare-adjacent ops, expect specialized platforms to eat generic tools—either go deep on a niche or integrate tightly with those that do.